SC Epcoritamab Combo Met ORR/PFS End Points in R/R Follicular Lymphoma
Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.